Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySelectHealth VNS & Intrathecal Pump Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedSelectHealthPolicy N/A

    Vagus Nerve Stimulation (VNS) — Neurology/Neurosurgery Coverage Criteria

    Customize your policy alerts

    Sign up for all SelectHealth policy alerts

    Know when SelectHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This SelectHealth policy governs coverage and clinical criteria for VNS devices and related neuromodulation procedures across Commercial, Medicare (CMS), and Community Care plans, including documentation, prior authorization, and exclusions described for multiple neurostimulation indications.

    Policy Summary
    PayerSelectHealth
    PolicyVagus Nerve Stimulation (VNS) — Neurology/Neurosurgery Coverage Criteria
    Policy CodePolicy N/A
    Change TypeCriteria revisions (intrathecal pump trial/permanent pump)
    Effective DateN/A
    Last ReviewMar 24, 2026
    Next Review DateFeb 2, 2026
    Key ActionVerify member benefits and obtain prior authorization documenting required conservative therapy and trial response (e.g., Modified Ashworth Scale) before requesting intrathecal pump placement.
    SourceLink
    POLICY UPDATE CHANGES

    For Commercial Plan Policy, replaced the Ashworth Scale with the Modified Ashworth Scale in criteria #B-2 for evaluation of this therapy.

    Modified requirements in criterion #A-1: 'Patient has intractable muscle spasticity.'

    Clarified requirements in criterion #B-2: 'Patient has a favorable response to a trial using intrathecal dosage of the anti-spasmodic drug prior to pump …'

    186Policy # (TOC)
    2026-03-24Last review
    CPT & HCPCS
    Billing code groups
    >=6wTrial requirement (spasticity)
    Not coveredNot covered (SPG/PNS)

    Coverage Criteria and Medical Necessity

    Initial surgical consideration

    Surgical fusion and decompression are considered when specific clinical and imaging criteria are met and conservative care has failed:

    General criteria: 1) Persistent or progressive symptoms attributable to the spine (axial pain or radiculopathy) with functional impairment; 2) Correlative diagnostic imaging (MRI or CT) demonstrating nerve root or spinal cord compression at the appropriate level; 3) Documentation of adequate prior conservative therapy — typically 6–12 months for axial lumbar pain, and 4–6 weeks may be appropriate for acute radiculopathy — unless emergent neurologic deficits are present; 4) Shared decision-making discussion documenting that risks, benefits, and alternative nonoperative options were reviewed.

    Derived from policy guidance on indications and conservative therapy; see imaging and timing recommendations.

    Conservative and interdisciplinary therapy

    When to prefer non-surgical or interdisciplinary options:

    Non-surgical alternatives: Offer structured conservative options before considering fusion for non-specific low back pain, including exercise programs, manual therapy (spinal manipulation/mobilization), acupuncture, pharmacologic therapy as appropriate, and intensive interdisciplinary rehabilitation with cognitive/behavioral emphasis; provocative discography is not recommended for routine diagnosis of chronic non-radicular low back pain.

    References: NICE and APS guidance noted in policy.

    Comparative effectiveness and harms

    Expected comparative outcomes and complications:

    Outcomes/risks: Surgical fusion may provide faster short-term symptom relief for selected patients, but long-term outcomes are often similar to conservative care; fusion is associated with higher rates of complications (including infection, adjacent segment disease, dysphagia, pseudoarthrosis, neurologic decline) and measurable reoperation rates, whereas conservative treatments have lower overall harms except in certain complications noted in trials.

    Complication rates and comparative effectiveness summarized from multiple trials and reviews.

    Coding and documentation guidance

    Coding and documentation: Procedures must be coded using the exact CPT and HCPCS codes listed in the policy and supported by clinical documentation that demonstrates the specific medical necessity criteria and guideline-based indications cited in the policy.

    Providers should document procedures corresponding to listed codes and include imaging, conservative therapy history, and indication-specific supporting data.

    Covered indications (DBS)

    Select Health covers deep brain stimulation when any one of the following criteria are met:

    Primary dystonia (generalized, segmental, hemidystonia, or cervical dystonia) when ALL of the following are met: a) age ≥ 7 years; AND b) chronic, intractable (drug-refractory) primary dystonia.

    From DBS coverage criteria.

    Essential tremor when tremor is resistant to all methods of conservative treatment and substantially impairs activities of daily living.

    From DBS coverage criteria.

    Parkinson disease: Parkinson's disease when ALL of the following are met: a) severe disability from disease; AND b) symptoms resistant to all methods of conservative treatment or when dystonic reactions to medical therapy occur.

    From DBS coverage criteria.

    Epilepsy when ALL of the following are met: a) age ≥ 18 years; AND b) evidence of focal/partial-onset epilepsy; AND c) not a resection candidate (multiple foci or patient declines resection); AND d) well-documented, debilitating seizure disorder; AND e) failure of 3 or more antiepileptic medications; AND f) failure of VNS or RNS is not required.

    DBS in Dystonia

    Evidence summary for dystonia

    DBS for primary dystonia: Randomized trial (Kupsch et al.) and multiple case series demonstrate effectiveness of DBS in primary dystonia with maintained improvements up to 30–36 months; studies generally exclude secondary dystonia and have limitations including small sample sizes and limited blinding.

    Evidence supports effectiveness in primary dystonia; secondary dystonia evidence insufficient.

    DBS in Parkinson Disease

    Evidence and candidate criteria for Parkinson disease

    PD candidate characteristics: Candidates should have received maximal medical therapy with a substantial (>50%) increase in 'off' time despite therapy; advanced Parkinsonism (Hoehn & Yahr III–IV, not V); at least two cardinal Parkinsonism symptoms; some response to dopaminergic therapy; age < 70 years; completed formal psychiatric evaluation without significant cognitive impairment or major psychiatric illness; request for bilateral DBS; and use of an FDA-approved device for the indication.

    Derived from policy candidate characteristics and systematic review summaries.

    DBS in Essential Tremor

    Essential tremor

    Essential tremor candidates: Patients with severe essential tremor that impairs activities of daily living despite maximally tolerated trials of beta blockers, benzodiazepines, and primidone or other appropriate antiepileptic medication may be considered for DBS.

    Candidate selection mirrors Parkinson's disease approach regarding refractory medical therapy.

    DBS in OCD

    Obsessive-compulsive disorder (OCD)

    OCD evidence stance: Available literature for DBS in OCD is primarily small case series and a small randomized sham-controlled trial; evidence strength is low and safety concerns (including higher adverse event rates) have been reported. Larger randomized trials of longer duration are needed to confirm efficacy and safety.

    FDA device approval referenced but policy concludes evidence remains limited.

    DBS in Epilepsy

    Epilepsy

    Epilepsy evidence: References include comparative analyses of neurostimulation technologies and studies of thalamic stimulation for drug-resistant partial epilepsy showing long-term efficacy and safety in selected reports.

    Policy cites Hayes and Neurology publications summarizing evidence for DBS in epilepsy.

    Commercial Plan Coverage

    Covered when device is FDA-approved for the indication

    Commercial coverage requirement: Interbody devices and similar implants are covered only for FDA‑approved indications; devices or uses not FDA‑approved are considered experimental/investigational and are not covered.

    Policy explicitly limits commercial coverage to FDA‑approved indications (StaXx XD example provided).

    Medicare and Community Care (Medicaid) Coverage

    Medicare: Coverage for Medicare members is determined by CMS; if CMS has an applicable determination it governs coverage decisions, otherwise SelectHealth commercial policy may apply when InterQual criteria are not available.

    Providers should consult the CMS Medicare Coverage Database for current determinations.

    Community Care (Medicaid) generally aligns with State of Utah Medicaid policy and may use InterQual or NCD/LCD criteria; when applicable, CMS or state determinations govern coverage for these plans.

    Refer to Utah Medicaid resources for current guidance.

    Criteria for placement of trial (temporary) pump

    Covered when ALL of the following are met for placement of a trial (temporary) pump:

    A-1: Patient has intractable muscle spasticity.

    Requirement for trial pump placement.

    A-2: Documentation of failure, contraindication, or intolerance to at least a 6‑week trial of oral antispasmodic drugs and physical therapy.>= 6 weeks

    Step-therapy requirement prior to trial pump placement.

    Criteria for placement of permanent pump

    Covered when ALL of the following are met for placement of a permanent pump:

    B-1: Meets all criteria required for trial pump placement (see A-1 and A-2).

    Prerequisite: successful trial criteria required.

    B-2: Patient has a favorable response to an intrathecal trial dose prior to pump placement, demonstrating improvement on the Modified Ashworth Scale, Spasm Scale, or activities of daily living (ADLs).

    Policy revision: Modified Ashworth Scale required per revision history.

    Not Covered — Surgical Migraine Interventions (Commercial/CHIP stance)

    Commercial Plan and CHIP coverage stance:

    Investigational/Unproven Surgical Procedures for Migraine: Select Health does NOT cover any surgical techniques used primarily for treatment of migraine headaches, including but not limited to PFO closure, corrugator/frontalis muscle resection, and contact‑point intranasal surgery, as evidence is inconclusive for safety and efficacy.

    Policy classifies these procedures as experimental/investigational for Commercial/CHIP plans.

    Investigational/Not Covered

    Investigational/Not Covered: Services described in the policy as investigational, experimental, or unproven for the specified indications are not covered under Select Health Commercial/CHIP plans.

    General investigational noncoverage statement.

    Device-specific exclusions (AIS)

    AIS device exclusions: Select Health does not cover posterior dynamic deformity correction devices (e.g., MIDC/ApiFix System) or anterior vertebral body tethering (e.g., Zimmer Biomet/The Tether) for progressive adolescent idiopathic scoliosis due to insufficient clinical data to support improved outcomes or long‑term safety.

    Device‑specific exclusions for AIS.

    Not covered — investigational

    Covered when ALL of the following are met

    Commercial plan coverage stance: Select Health commercial plan does NOT cover peripheral nerve stimulation for occipital neuralgia or chronic headaches as it is considered experimental/investigational.

    Policy statement of noncoverage for PNS in these indications.

    Not covered — investigational/experimental/unproven (coverage stance and rationale)

    Coverage stance and rationale

    Investigational/Unproven: Peripheral/occipital nerve stimulation for occipital neuralgia or chronic headaches is considered investigational/experimental/unproven based on limited and inconsistent evidence, modest effect sizes in trials (mean ~2.56 fewer headache days/month in meta-analysis), methodological challenges, and notable device complication rates (eg, lead migration and infections).

    Rationale summarized from systematic reviews and RCTs.

    Investigational / Not Covered — insufficient evidence across indications

    Not covered for the indications discussed when evidence is insufficient

    QEEG investigational status: Quantitative electroencephalography (QEEG/brain mapping) is considered investigational/experimental/unproven for the indications discussed due to formative-stage research, small sample sizes, and insufficient evidence to justify clinical use for these diagnostic or treatment decisions.

    Policy billing/coding statement: Not Covered for these indications.

    Covered when all the following are met — responsive cortical neurostimulation criteria

    SelectHealth covers responsive cortical neurostimulation when ALL of the following are met:

    Age: Patient is 12 years of age or olderage >= 12

    Criterion 1 from RNS policy

    Seizure type: Partial (focal) onset seizures

    Criterion 2 from RNS policy

    Localization: Diagnostic testing localizes no more than two (2) epileptogenic foci<= 2 foci

    Criterion 3 from RNS policy

    Medication failure:

    Not covered (Commercial/CHIP) — SPG blocks coverage determination

    SelectHealth Commercial and CHIP coverage determination

    Commercial plan noncoverage: Select Health does NOT cover sphenopalatine ganglion (SPG) blocks for any indication, including acute or chronic headaches and complex regional pain syndrome (CRPS), because current evidence is insufficient to determine efficacy and safety.

    Applies to Commercial and CHIP plans.

    Imaging and fusion decisions should follow guideline-based conservative care principles: for adults <50 years without systemic signs or symptoms, routine advanced imaging is not indicated and symptomatic therapy without imaging is appropriate. Advanced imaging (eg, MRI/CT) should be reserved for patients who are considering surgery or when systemic disease is suspected. For radiculopathy, MRI is appropriate if bilateral symptoms, urinary retention, or failure to improve after a conservative course (typically 4–6 weeks) are present. Documented correlation between imaging findings and the level(s) of clinical symptoms is required when fusion or decompression is proposed.

    Within the code and coverage listings included in these chunks there are no additional explicit exclusion statements beyond those articulated elsewhere in the policy documents. Providers should therefore rely on the specific exclusion sections and device- or indication-level not-covered statements present elsewhere in the policy when determining noncoverage.

    Deep brain stimulation (DBS) is explicitly listed as NOT covered for obsessive‑compulsive disorder. The policy also treats DBS for secondary dystonias (other than those associated with Parkinson disease or essential tremor) as investigational due to insufficient evidence: most DBS dystonia trials focus on primary dystonia and include too few secondary dystonia patients to establish effectiveness.

    The evidence base for DBS in patients with secondary dystonia is limited: published studies are predominantly small case series with few patients and therefore do not permit conclusions regarding effectiveness in secondary dystonia. This limitation underlies the investigational stance for these patients.

    Patients with severe, limiting comorbidities (for example, Class III–IV angina pectoris, Stage III or higher congestive heart failure, or debilitating arthritis) are considered contraindicated for DBS procedures. Such comorbidities should be documented and may preclude implantation.

    The StaXx XD Expandable Device is not covered for interbody fusion because it is not FDA‑approved for that indication. The policy notes that SelectHealth covers interbody devices only for FDA‑approved indications, and use of a device outside its approved indications meets the plan definition of experimental/investigational and will be denied.

    Contraindications to intrathecal baclofen (pump) therapy include hypersensitivity to baclofen and general surgical contraindications (eg, sepsis, coagulopathy). Documentation of these contraindications must be present as they preclude trial or permanent pump placement.

    Surgical techniques performed primarily to treat migraine (for example, PFO closure, corrugator/frontalis muscle resection, and intranasal 'contact point' surgery) are classified as experimental/investigational and are NOT covered under the Commercial plan and CHIP, based on inconclusive evidence of safety and efficacy.

    Posterior dynamic deformity correction devices (eg, MIDC/ApiFix) and anterior vertebral body tethering (eg, The Tether) for progressive adolescent idiopathic scoliosis are not covered. The policy states there is insufficient clinical data demonstrating improved outcomes or long‑term safety, so these device‑based scoliosis correction approaches are considered experimental/investigational.

    SelectHealth considers peripheral nerve stimulation (PNS) for occipital neuralgia and chronic headaches investigational and not covered under the Commercial plan. The policy cites small, unblinded studies, limited randomized data with mixed or inconclusive primary endpoints, modest average effects in meta-analysis, and notable device complications (eg, lead migration, infection) as the rationale for noncoverage.

    Peripheral nerve stimulation for the indications discussed is specifically listed in the policy as Not Covered: Investigational/Experimental/Unproven. Providers should expect noncoverage for these indications and should document alternative care plans if proposed.

    The American Academy of Neurology guideline (2016) advises against using QEEG measures such as the theta/beta power ratio or frontal beta power to replace a standard clinical evaluation for ADHD. The policy summarizes that QEEG applications remain largely formative and insufficient to support routine clinical use for the indications reviewed.

    Medicare coverage is governed by CMS determinations; when a CMS NCD/LCD exists it controls Medicare coverage. Community Care (Medicaid) policies typically align with state Medicaid (eg, Utah Medicaid) and may use InterQual; if CMS or state determinations are not available, SelectHealth commercial policy may apply. Providers must verify plan‑specific coverage and prior authorization requirements in each case.

    SelectHealth does NOT cover sphenopalatine ganglion (SPG) blocks for any indication under the Commercial plan (including acute or chronic headaches and CRPS). The policy cites limited and mixed evidence from small trials and pilot studies that suggest possible short‑term effects but lack consistent durable clinically significant benefit; therefore SPG blockade is considered investigational and not covered.

    Provocative discography is not recommended as a diagnostic procedure for chronic non‑radicular low back pain. The policy references guideline guidance that discourages routine use of provocative discography in this context.

    Within the chunks cited there are no explicit standalone statements labelled 'not medically necessary.' Coverage determinations in this policy are presented as covered, not covered (investigational/experimental), or as specific device/indication exclusions rather than using that phrase in these excerpts.

    Several investigational uses for DBS are described in the policy context where evidence is limited (small case series, limited RCT data) and safety concerns have been raised. The policy highlights that for indications such as treatment‑resistant OCD and certain dystonias, the literature is preliminary, effect durability and safety are uncertain, and larger randomized trials are needed before routine coverage can be supported.

    For treatment‑resistant obsessive‑compulsive disorder, DBS evidence consists mainly of small series and a single small randomized sham‑controlled trial; the policy notes the low strength of evidence and concerns about adverse events, concluding that current evidence is insufficient to prove efficacy and safety for routine coverage of DBS in OCD.

    The policy states that procedures categorized as investigational, experimental, or unproven for a given indication are not covered. This includes interventions for which available trials are small, uncontrolled, or demonstrate modest effects with important device‑related safety issues; such services may be denied as not covered.

    Evidence limitations and safety concerns are repeatedly cited as the basis for investigational or not‑covered designations: small sample sizes, lack of blinding or control groups, modest effect sizes in pooled analyses, and device complications such as lead migration and infection are specifically referenced as reasons to classify a therapy as investigational.

    QEEG (brain mapping) services for the indications discussed are listed as Not Covered: Investigational/Experimental/Unproven. The policy notes the formative state of the literature and guideline cautions (eg, AAN guidance) against substituting QEEG metrics for standard clinical evaluation.

    The policy concludes that current evidence is insufficient to establish consistent, durable benefit for SPG blockade in migraine and headache disorders. Although small pilot studies report short‑term relief in some patients, larger controlled trials with durable clinical endpoints are lacking; accordingly SPG blockade is considered investigational and not covered for Commercial/CHIP members.

    Billing Codes and Coding Guidance

    CPT Codes listedCPT
    0275TPercutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar.
    22533Arthrodesis, lateral extracavitary technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar.
    22534Each additional vertebral segment (List separately in addition to code for primary procedure).
    22551Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below C2.
    22552Each additional interspace (List separately in addition to code for separate procedure).
    22554Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below C2.
    22558Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar.
    22585Arthrodesis, anterior interbody technique, each additional interspace (List separately in addition to code for primary procedure).
    22600Arthrodesis, posterior or posterolateral technique, single level; cervical below C2 segment.
    22612Arthrodesis, posterior or posterolateral technique; lumbar (with lateral transverse technique, when performed).
    1–10 of 16
    1/2
    Covered CPT CodesCPTCovered
    0275TPercutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements...
    22533Arthrodesis, lateral extracavitary technique, including minimal discectomy to prepare interspace; lumbar.
    22534each additional vertebral segment (List separately in addition to code for primary procedure).
    22551Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression; cervical below C2.
    22552each additional interspace (List separately in addition to code for separate procedure).
    22554Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace; cervical below C2.
    22558Arthrodesis, anterior interbody technique; lumbar.
    22585Arthrodesis, anterior interbody technique, each additional interspace.
    22600Arthrodesis, posterior or posterolateral technique, single level; cervical below C2.
    22612Arthrodesis; lumbar (with lateral transverse technique, when performed).
    1–10 of 37
    1/4
    HCPCS CodesHCPCSCovered
    C2614Probe, percutaneous lumbar discectomy
    Coding guidance (informational)mixed
    CPT codes referenced indirectlyDocument notes that codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of codes does not constitute coverage.
    CPT CODESCPTCovered
    61863Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site, first array
    61864Each additional array (list separately)
    61867Stereotactic implantation with intraoperative micro-electrode recording; first array
    61868Each additional array with micro-electrode recording
    61880Revision or removal of intracranial neurostimulator electrode
    61885Insertion or replacement of cranial neurostimulator pulse generator or receiver; connection to single electrode array
    61886Insertion or replacement with connection to two or more electrode arrays
    61888Revision or removal of cranial neurostimulator pulse generator or receiver
    95970Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming
    95983Electronic analysis with brain neurostimulator programming, first 15 minutes
    1–10 of 11
    1/2
    HCPCS CODESHCPCSCovered
    C1767Generator, neurostimulator (implantable), nonrechargeable
    C1778Lead, neurostimulator (implantable)
    C1787Patient programmer, neurostimulator
    C1816Receiver and/or transmitter, neurostimulator (implantable)
    C1820Generator, neurostimulator (implantable), with rechargeable battery and charging system
    C1822Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
    C1897Lead, neurostimulator test kit (implantable)
    L8679Implantable neurostimulator, pulse generator, any type
    L8680Implantable neurostimulator electrode, each
    L8681Patient programmer (external) for use with implantable programmable neurostimulator, replacement only
    1–10 of 16
    1/2
    CPT CODES (from adjacent policy content)CPT
    62320Injection(s), of diagnostic or therapeutic substance(s) interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance
    62321Injection(s), of diagnostic or therapeutic substance(s) interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance
    62322Injection(s), of diagnostic or therapeutic substance(s) interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance
    62323Injection(s), of diagnostic or therapeutic substance(s) interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance
    64450Injection, anesthetic agent; other peripheral nerve or branch
    77003Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures
    HCPCS CODES (from adjacent policy content)HCPCS
    J2400Injection, chloroprocaine HCl, per 30 ml
    CPT codes referencedCPT
    20936Autograft for spine surgery only (includes harvesting the graft); local (e.g., ribs, spinous process, or laminar fragments) obtained from same incision (List separately in addition to code for primary procedure).
    20937Autograft, morselized (through separate skin or fascial incision) (List separately in addition to code for primary procedure).
    22633Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace, single interspace and segment; lumbar.
    22634Each additional interspace and segment (List separately in addition to code for primary procedure).
    22842Posterior segmental instrumentation; 3 to 6 vertebral segments (List separately in addition to code for primary procedure).
    22853Insertion of interbody biomechanical device(s) with integral anterior instrumentation to intervertebral disc space in conjunction with interbody arthrodesis, each interspace.
    22854Insertion of intervertebral biomechanical device(s) with integral anterior instrumentation to vertebral corpectomy defect in conjunction with interbody arthrodesis, each contiguous defect.
    22859Insertion of intervertebral biomechanical device(s) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect.
    63047Laminectomy, facetectomy and foraminotomy, single vertebral segment; lumbar.
    63048Each additional segment, cervical, thoracic, or lumbar (List separately in addition to code for primary procedure).
    HCPCS codesHCPCS
    No codes listed
    Catheter PlacementCPTCovered
    62350Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; without laminectomy
    62351Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; with laminectomy
    62355Removal of previously implanted intrathecal or epidural catheter
    Reservoir/Pump PlacementCPTCovered
    62360Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir
    62361Implantation or replacement; non-programmable pump
    62362Implantation or replacement; programmable pump, including preparation of pump, with or without programming
    62365Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion
    Analysis/Reprogramming and RefillsCPTCovered
    62367Electronic analysis of programmable, implanted pump; without reprogramming or refill
    62368Electronic analysis of programmable, implanted pump; with reprogramming
    62369Electronic analysis of programmable, implanted pump; with reprogramming and refill
    62370Electronic analysis of programmable, implanted pump; with reprogramming and refill (requiring skill of a physician or other qualified health care professional)
    95990Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed
    95991Refilling and maintenance of implantable pump or reservoir; requiring physician's skill or other qualified health care professional
    96521Refilling and maintenance of portable pump
    96522Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (eg, intravenous, intra-arterial)
    HCPCS / drug and device codesHCPCSCovered
    J0475Injection, baclofen, 10 mg
    J0476Injection, baclofen, 50 mcg for intrathecal trial
    A4220Refill kit for implantable infusion pump
    A4221Supplies for maintenance of drug infusion catheter, per week (list drug separately)
    C1772Infusion pump, programmable (implantable)
    C1891Infusion pump, non-programmable, permanent (implantable)
    C2626Infusion pump, non-programmable, temporary (implantable)
    E0782Infusion pump, implantable, non-programmable (includes all components)
    E0783Infusion pump, implantable, programmable (includes all components)
    E0785Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement
    1–10 of 11
    1/2
    Forehead/Brow LiftCPTNot Covered
    15824Rhytidectomy, forehead
    Forehead/Brow LiftCPT
    15824Rhytidectomy, forehead
    Excision or Submucous Resection of Nasal TurbinatesCPT
    30130Excision turbinate, partial or complete, any method
    30140Submucous resection turbinate, partial or complete, any method
    Nasal Septum RepairCPT
    30520Septoplasty or submucous resection, with or without cartilage scoring, contouring or replacement with graft
    Patent Foramen OvaleCPT
    93580Percutaneous transcatheter closure of congenital interatrial communication (i.e., Fontan fenestration, atrial septal defect) with implant
    Additional ProceduresCPT
    93315Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report
    93320Doppler echocardiography, pulsed wave and/or continuous wave with spectral display; complete
    93321Doppler echocardiography; follow-up or limited study
    93325Doppler echocardiography color flow velocity mapping
    93533Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies
    CPT codes listed in this portion of the document (spine/tethering related)CPT
    0656TVertebral body tethering, anterior; up to 7 vertebral segments
    0657TVertebral body tethering, anterior; 8 or more vertebral segments
    20930Allograft, morselized, or placement of osteopromotive material, for spine surgery only
    20931Allograft, structural, for spine surgery only
    20936Autograft for spine surgery only; local
    20937Autograft for spine surgery only; morselized (through separate skin or fascial incision)
    20938Autograft for spine surgery only; structural bicortical or tricortical (through separate skin or fascial incision)
    22612Arthrodesis, posterior or posterolateral technique, single level; lumbar (with lateral transverse technique, when performed)
    22800Arthrodesis, posterior, for spinal deformity, with or without cast; up to 6 vertebral segments (levels)
    +22840Posterior non-segmental instrumentation
    1–10 of 13
    1/2
    CPT Codes listedCPT
    64555Percutaneous implantation of neurostimulator electrodes; peripheral nerve (excludes sacral nerve)
    64575Incision for implantation of neurostimulator electrodes; peripheral nerve (excludes sacral nerve)
    64585Revision or removal of peripheral neurostimulator electrode array
    64590Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
    64595Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
    95970Electronic analysis of implanted neurostimulator pulse generator system; simple or complex, without reprogramming
    95975Electronic analysis of implanted neurostimulator pulse generator system; complex cranial nerve neurostimulator with programming, each additional 30 minutes after first hour
    HCPCS Codes listedHCPCS
    C1767Generator, neurostimulator (implantable), non-rechargeable
    C1778Lead, neurostimulator (implantable)
    C1787Patient programmer, neurostimulator
    C1816Receiver and/or transmitter, neurostimulator (implantable)
    C1883Adaptor/extension, pacing lead or neurostimulator lead (implantable)
    C1897Lead, neurostimulator test kit (implantable)
    CPT CODES listedCPT
    95955Electroencephalogram (EEG) during nonintracranial surgery (e.g., carotid surgery)
    95957Digital analysis of electroencephalogram (EEG) (e.g., for epileptic spike analysis)
    95961Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes; initial hour
    95962Functional cortical and subcortical mapping; each additional hour
    HCPCS CODES listedHCPCS
    S8040Topographic brain mapping
    Covered CPT CodesCPTCovered
    61850Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical.
    61860Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical.
    61863Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site; first array.
    61864Each additional array (List separately in addition to primary procedure).
    61880Revision or removal of intracranial neurostimulator electrodes.
    61885Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array.
    61886Insertion or replacement of cranial neurostimulator electrodes.
    61888Revision or removal of cranial neurostimulator pulse generator or receiver.
    95976Electronic analysis of implanted neurostimulator pulse generator/transmitter; simple cranial nerve neurostimulator programming.
    95977Electronic analysis of implanted neurostimulator pulse generator/transmitter; complex cranial nerve neurostimulator programming.
    1–10 of 12
    1/2
    Covered HCPCS/HCPCS-II CodesHCPCSCovered
    C1767Generator, neurostimulator (implantable), nonrechargeable
    C1778Lead, neurostimulator (implantable)
    L8679Implantable neurostimulator, pulse generator, any type
    L8680Implantable neurostimulator, electrode, each
    L8681Patient programmer (external) for use with implantable programmable neurostimulator radiofrequency receiver
    L8682Implantable neurostimulator radiofrequency receiver
    L8683Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
    L8686Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
    L8687Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
    1–10 of 11
    1/2
    CPT CODESCPT
    64505Injection, anesthetic agent, sphenopalatine ganglion
    HCPCS CODESHCPCS
    No codes listed
    inv-74: List-separate codes — add-on coding guidance for additional interspace/segment
    Add-on coding guidanceMany spinal procedure CPTs include 'each additional interspace/segment' which must be billed as separate add-on codes (e.g., 22534, 22552, 22585, 22632, 22634, 63035, 63043, 63044, 63048)

    Provider Actions, Prior Authorization, and Documentation

    Note

    Coverage determination sources and applicability

    Select Health coverage determinations vary by product line. For Medicare members, CMS/NCD/LCD determinations govern; if no CMS decision exists and InterQual is unavailable, the SelectHealth commercial policy applies. Select Health Community Care (Medicaid) generally aligns with Utah Medicaid and InterQual; exceptions may occur. Policies are subject to change without notice. Providers must verify the member's individual benefits and eligibility at the time of request and confirm prior authorization requirements per contract before providing services.

    • Medicare members: defer to CMS coverage determinations first.
    • Medicaid members: typically follow Utah Medicaid/InterQual alignment.
    • Commercial/CHIP: apply Select Health commercial policy unless CMS/InterQual dictate otherwise.
    • Policies may be amended without notice; verify at time of service.
    Prior Authorization

    Prior authorization requirements and plan dependence

    Background, Scope and Context

    Background: This document set comprises multiple neurosurgical device and procedure policies. The Table of Contents includes Vagus Nerve Stimulation (Policy #186) along with related policies covering DBS, PNS, intrathecal pumps, spinal fusion, SPG blocks, and others; SelectHealth applies evidence reviews and external guidelines to inform coverage decisions across these topics.

    Definitions and Key Terms

    inv-140: Adjacent segment disease (ASD) definition
    Adjacent segment disease (ASD) definitionDegenerative changes and symptomatic disease occurring at spinal levels adjacent to a prior fusion, reported to develop after anterior cervical discectomy and fusion
    Clinical implicationASD may present months to years after index fusion and was reported in series with notable reoperation rates (eg, Bydon et al.)
    Common levelsASD most frequently reported at levels immediately above the index fusion (eg, C5/C6, C6/C7 in cervical ACDF series)
    inv-141: Conservative management for LBP
    Conservative management componentsActivity modification, education, exercise programs, manual therapy, heat/cold, limited bed rest with gradual return to activity, and pharmacotherapy (non‑narcotic analgesics preferred)
    First-line approach

    Policy Changes and Revision History

    2025-12-15clarification

    Modified requirements in criterion A-1 to specify 'Patient has intractable muscle spasticity' and clarified expectations for documentation of favorable trial response in criterion B-2.

    2024-10-28updateLatest

    Replaced the Ashworth Scale with the Modified Ashworth Scale in permanent pump evaluation criterion B-2 for Commercial Plan policy.

    Policy Summary
    PayerSelectHealth
    PolicyVagus Nerve Stimulation (VNS) — Neurology/Neurosurgery Coverage Criteria
    Policy CodePolicy N/A
    Change TypeCriteria revisions (intrathecal pump trial/permanent pump)
    Effective DateN/A
    Last ReviewMar 24, 2026
    Next Review DateFeb 2, 2026
    Key ActionVerify member benefits and obtain prior authorization documenting required conservative therapy and trial response (e.g., Modified Ashworth Scale) before requesting intrathecal pump placement.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityBilling Codes and Coding GuidanceProvider Actions, Prior Authorization, and DocumentationBackground, Scope and ContextDefinitions and Key TermsPolicy Changes and Revision History

    From DBS coverage criteria.

    Refractory to two or more antiepileptic medications
    >= 2 failed AEDs

    Criterion 4 from RNS policy

    Seizure frequency: Average of one or more disabling seizures per month over the most recent three months>=1/month averaged over 3 months

    Criterion 5 from RNS policy

    Alternative therapies considered: Documentation that the care team has considered vagus nerve stimulation (VNS) or surgical ablation and documented reasons the patient is not a candidate

    Criterion 6 from RNS policy

    Typical add-on codes (examples)22534 (each additional vertebral segment); 22552 (each additional interspace); 22632 (each additional interspace for posterior interbody); 22634 (each additional interspace and segment)
    Procedure types requiring list-separate codesAnterior/posterior interbody arthrodesis, laminotomy/laminectomy with 'each additional interspace' descriptors, and multilevel fusion instrumentation
    inv-75: Antiepileptic drug failures — requirement (>= 3 medications)
    Required antiepileptic medication failuresFailure of 3 or more antiepileptic medications is required prior to consideration of neurosurgical neurostimulation for epilepsy (DBS criterion specifies 'Failure of 3 or more antiepileptic medications')
    RNS medication failure standard (related)Responsive cortical neurostimulation criteria require being refractory to two or more antiepileptic medications (policy distinguishes thresholds between technologies)
    Documentation expectationClinical documentation should list prior AEDs tried, durations, responses, and reasons for discontinuation/intolerance
    inv-76: Minimum age for DBS for epilepsy — >= 18 years
    Minimum age for DBS in epilepsyAge ≥ 18 years is required for DBS consideration in epilepsy per SelectHealth DBS criteria
    Contrast with RNS ageResponsive cortical neurostimulation (RNS) criteria use age ≥ 12 years for coverage — different devices have different minimum ages
    Documentation noteProvider documentation should clearly record patient's date of birth/age to confirm eligibility
    inv-77: Oral antispasmodic trial duration — >= 6 weeks
    Oral antispasmodic trial duration>= 6 weeks of oral antispasmodic drugs (plus physical therapy) required before trial intrathecal pump placement
    Context for intrathecal therapyDocumentation must show failure, contraindication, or intolerance to the 6‑week oral trial prior to trial pump consideration
    Assessment scales for responseTrial and subsequent permanent pump criteria require improvement measured by Modified Ashworth Scale, Spasm Scale, or ADLs
    inv-78: Seizure frequency — average >=1 disabling seizure/month over most recent 3 months
    Seizure frequency thresholdAverage of ≥1 disabling seizure per month over the most recent 3 months is required for responsive cortical or neurostimulation candidacy
    Seizure type requirementSeizures must be partial (focal) onset as documented by diagnostic testing
    Localization requirementDiagnostic testing must localize no more than two epileptogenic foci

    Prior authorization is required for many spine fusion, neuromodulation, implantable device, and related procedures. Authorization requirements (including exact CPT/HCPCS codes, documentation of conservative therapy failure, trial periods, and device details) depend on the member's benefit plan and must be confirmed prior to scheduling.

    • Authorization required for spinal fusion and combined decompression/fusion procedures and commonly billed CPTs (see code lists).
    • Authorization required for DBS, RNS, PNS, intrathecal pump implantation/maintenance, and other implantable neurostimulator services and associated HCPCS device codes.
    • Prior authorization rules vary by plan — verify via member contract, customer service, or Provider Relations (801-442-3692).
    Documentation Required

    Conservative care, imaging, and trial requirements

    Providers should document conservative therapy attempts and durations before authorization for fusion or related spine surgery. For lumbar fusion, conservative care (medical management, physical therapy, injections, exercise, cognitive/behavioral rehab) is generally expected and often tried for 6–12 months; for imaging and escalation, document failure to improve after 4–6 weeks when relevant. For intrathecal baclofen, a documented ≥6-week trial of oral antispasmodics plus physical therapy is required prior to trial pump placement; permanent pump requires a successful intrathecal trial with objective improvement (e.g., Modified Ashworth Scale).

    • Lumbar conservative care typically 6–12 months before fusion is considered; document types, duration, and functional findings.
    • MRI reserved for patients who fail conservative therapy or have red flags; imaging not routinely recommended for adults <50 without systemic signs.
    • Intrathecal baclofen: document intractable spasticity, failure/contraindication/intolerance to ≥6-week oral antispasmodic trial and PT; trial pump response documented with Modified Ashworth/Spasm/ADL improvement.
    Billing Rule

    Procedure and device codes referenced for authorization and billing

    Select Health requires prior authorization for specific CPT and HCPCS codes related to spinal fusion, neuromodulation, implantation, revision/removal, and device supplies. Code lists included in policies are informational and may trigger denials if submitted without required documentation or without verifying member benefits. Providers must bill using the applicable CPT/HCPCS codes and include device/supply codes where applicable.

    • Spinal fusion CPTs (e.g., 22533, 22551, 22630, 22632, 22633, 22634, 22612, 22614, 22630 series) and related HCPCS.
    • DBS/RNS/RNS-related CPTs (e.g., 61850, 61860, 61863–61868, 61880, 61885–61888) and device HCPCS/L-codes (C1767, C1778, L8679–L8688, etc.).
    • PNS CPTs (e.g., 64555–64595, 95970, 95975) and associated HCPCS device codes (C1767, C1778, C1897, etc.).
    • Interbody device and fusion device CPT/HCPCS (20936–20937, 22633–22634, 22842, 22853–22859, 63047–63048).
    Denial Risk

    Coverage stance — investigational / not covered services

    Coverage stance: Select Health classifies some procedures as investigational/unproven and not covered for the listed indications (for example, peripheral nerve stimulation for occipital neuralgia/chronic headaches, certain migraine surgical techniques, StaXx XD interbody device, SPG blocks). Services considered investigational will be denied when billed for those indications.

    • PNS for occipital neuralgia/chronic headaches — Not covered (investigational).
    • Migraine surgical procedures used primarily for migraine — Not covered (investigational).
    • StaXx XD Expandable Device for interbody fusion — Not covered (not FDA approved for indication).
    • SPG blocks — Not covered for any indication (commercial).
    • QEEG services remain investigational for the discussed indications and are Not Covered.
    Documentation Required

    Required clinical documentation and common denial triggers

    Documentation must support all requests for prior authorization. Providers should include exact procedures corresponding to billed CPT codes, clinical rationale, prior conservative care details (types, dates, response), imaging and objective findings, trial results (e.g., temporary lead trials for neuromodulation of ~1 week), psychiatric screening results for DBS, medication trials (e.g., failure of ≥3 AEDs for epilepsy DBS criteria or failure of ≥2 AEDs for RNS per policy), age, seizure burden, localization studies for RNS (≤2 foci), and device details. Missing or inadequate documentation (e.g., lack of intractable spasticity documentation or failed oral therapy for intrathecal baclofen) may result in denial.

    • Record exact CPT/HCPCS codes and corresponding operative procedure descriptions.
    • Support conservative care: list therapies, durations, objective response, and physical findings.
    • Neuromodulation documentation: trial duration/results (~1 week temporary electrode trial), psychological screening, device model and implant details, and programming/analysis reports (95970–95977 series where applicable).
    • DBS for PD: document maximal medical therapy, Hoehn & Yahr stage and dopaminergic response, psychiatric clearance, and planned bilateral stimulation.
    • Epilepsy neurostimulation: document age, focal/partial onset, seizure frequency (≥1 disabling/month over last 3 months for RNS), failure of specified AED trials, and localization to ≤2 foci.
    Billing Rule

    Billing/coding informational notice and claim filing guidance

    Coding and billing notes: code lists in policies are informational only and do not guarantee coverage. Include applicable CPT and HCPCS device/supply codes on claims. Providers should verify member benefits before service. Coding errors or omission of device HCPCS/L-codes may lead to payment denial or claim delays.

    • Include CPT procedure codes and HCPCS/L-codes for implanted devices and supplies on claims.
    • Coding lists may trigger denials if billed incorrectly or without prior auth/documentation.
    • Contact Provider Relations or Member Customer Service for benefit questions; verify benefit/authorization prior to service.
    Step Therapy

    Step therapy, medication failure, and alternative therapy considerations

    Step-therapy and trial expectations vary by policy and indication. Where specified: epilepsy for DBS requires failure of 3 or more AEDs; RNS requires refractory seizures despite ≥2 AEDs and localization to ≤2 foci; essential tremor and PD require failure/intolerance to maximal medical therapy. Some policies require consideration of alternative therapies (e.g., VNS or surgical ablation before RNS) and documentation of contraindications or reasons alternatives are not appropriate. For several indications, explicit step-therapy is not specified due to limited or inconclusive evidence.

    • DBS (epilepsy): failure of ≥3 antiepileptic medications required.
    • RNS (responsive cortical neurostimulation): refractory to ≥2 AEDs; consider VNS or surgical ablation and document reasons if not pursued.
    • Essential tremor/PD for DBS: document failure or contraindication to medical therapy and maximal tolerated medical therapy.
    • Intrathecal baclofen: documented failure/intolerance/contraindication to ≥6-week oral antispasmodic trial plus PT required before trial pump.
    Comprehensive nonoperative care is first-line for chronic cervical and lumbar pain; surgery considered only after failure of conservative therapy
    Specific guidanceChou and Huffman concluded therapies with moderate evidence include cognitive‑behavioral therapy, exercise, spinal manipulation, and interdisciplinary rehabilitation
    inv-142: Percutaneous laminotomy/laminectomy (0275T)
    0275T descriptionPercutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy; lumbar
    Approach and guidancePerformed under indirect image guidance (eg, fluoroscopic, CT), can be unilateral or bilateral, single or multiple levels
    Billing note0275T is listed among CPT codes in the spinal fusion/decompression section and should be billed per coding guidance
    inv-143: C2614 HCPCS code definition
    C2614 HCPCS definitionC2614 — Probe, percutaneous lumbar discectomy
    Use contextC2614 is listed in the policy's HCPCS section supporting percutaneous lumbar discectomy billing
    Billing implicationInclude HCPCS C2614 on claims for probe-based percutaneous lumbar discectomy when appropriate
    inv-144: Dystonia definition
    Dystonia definitionDystonia is a neurological movement disorder with involuntary muscle contractions causing abnormal postures or movements
    Epidemiology contextDystonia affects approximately 250,000 people in the U.S. and is a commonly discussed DBS indication
    Clinical relevancePrimary dystonia (generalized/segmental/cervical) with drug‑refractory symptoms is an accepted DBS indication
    inv-145: Essential tremor definition
    Essential tremor definitionEssential tremor is a nerve disorder characterized by uncontrollable shaking (tremors) often affecting hands, arms, head, larynx, or voice; lower body is rarely affected
    Relative prevalenceEssential tremor is one of the most common movement disorders and a primary indication for DBS when refractory to medical therapy
    Candidate requirement (policy context)DBS for essential tremor is considered when tremor is resistant to all methods of conservative treatment
    inv-146: Parkinson's disease definition
    Parkinson's disease definitionParkinson's disease is a neurodegenerative disorder caused by loss of dopamine‑producing cells, characterized by resting tremor, bradykinesia, and rigidity
    Clinical featuresCore features include tremor, slowness of movement, and limb rigidity which may respond to dopaminergic therapy
    DBS relevanceDBS is a treatment option for advanced Parkinson's disease when medical therapy is insufficient
    inv-147: Advanced Parkinsonism candidate characteristics
    Advanced Parkinsonism candidate characteristicPatient has received maximal medical therapy with a substantial (>50%) increase in 'off' time despite therapy
    Disease stage and age limitsHoehn & Yahr stage III–IV (not stage V) and age <70 years are recommended candidate criteria
    Additional requirementsAt least two cardinal Parkinsonism symptoms present, some response to dopaminergic therapy, completed formal psychiatric evaluation without significant cognitive impairment, and request for bilateral DBS with an FDA‑approved device
    inv-148: Interbody fusion device definition
    Interbody fusion device definitionDevice that acts as a disc spacer and holds bone graft, often with integrated fixation to maintain stability by purchase into vertebral endplates
    Typical formOften a hollow cylinder or rectangular box made of metal or polymer with integrated fixation
    Intended functionMaintains disc height, supports bone grafting, and provides mechanical stability for arthrodesis
    inv-149: PEEK definition
    PEEK definitionPEEK (polyetheretherketone) is a radiolucent thermoplastic polymer used to make cages and spacers that mimic bone elasticity and resistance to compression loading
    Device examplesPEEK is used in interbody cages (eg, Avenue L Interbody Fusion System uses PEEK OPTIMA LT1) and may incorporate embedded titanium alloys
    Clinical notePEEK's radiolucency facilitates imaging assessment of fusion and is commonly used in interbody devices
    inv-150: Intrathecal baclofen (IB) therapy definition
    Intrathecal baclofen (IB) therapy definitionSurgical implantation of a programmable infusion pump and intrathecal catheter to deliver baclofen directly into the intrathecal space for long‑term management of intractable spasticity
    Therapeutic rationaleIB allows therapeutic drug levels at the site of action with much lower systemic plasma concentrations compared with high‑dose oral baclofen
    Patient populationPrimarily used for spasticity of spinal or cerebral origin (eg, spinal cord injury, MS, cerebral palsy) when oral therapy is insufficient or causes intolerable side effects
    inv-151: Modified Ashworth Scale / Spasm Scale — note for evaluation of intrathecal therapy
    Modified Ashworth Scale / Spasm ScaleClinical scales used to document response to intrathecal baclofen: Modified Ashworth measures muscle tone (0–4 scale variants) and Spasm Scale quantifies spontaneous spasms per hour (0–4)
    Use in decision-makingImprovement in Modified Ashworth Scale, Spasm Scale, or ADLs is required to demonstrate favorable response to trial prior to permanent pump placement
    Operational updatePolicy revision replaced 'Ashworth Scale' with 'Modified Ashworth Scale' in permanent pump criteria
    inv-152: PFO closure definition
    PFO closure definitionPercutaneous device closure of a patent foramen ovale to stop abnormal right‑to‑left atrial shunting; evaluated for possible migraine benefit
    Procedure descriptionClosure is performed via femoral venous catheterization with an expandable implant that permanently occludes the PFO
    Migraine evidence contextPFO closure has been studied for migraine prevention but is not established for primary migraine prophylaxis
    inv-153: Cranial muscle surgery definition
    Cranial muscle surgery definitionSurgical resection of muscles (eg, corrugator supercilii, procerus) or portions of nerves identified as migraine triggers after positive Botox response testing
    Patient selectionCandidates are typically those with ≥50% improvement from botulinum toxin A and identifiable trigger points
    Procedure goalAim is to reduce peripheral nerve compression thought to trigger migraine headaches
    inv-154: Intranasal (contact point) surgery definition
    Intranasal (contact point) surgery definitionSurgical correction of nasal anatomical contact points (eg, septoplasty, turbinectomy) in patients with radiographic contact points and topical anesthetic response
    Candidate identificationPatients selected based on imaging showing contact points and symptomatic improvement with topical anesthetic to the contact area
    Evidence qualityAvailable studies are largely uncontrolled retrospective series; results suggest benefit in selected patients but evidence is limited
    inv-155: Investigational/Experimental/Unproven definition
    Investigational/Experimental/Unproven (policy definition)Procedures or treatments for which insufficient evidence exists to support clinical benefit for the specified indication; such services are classified as investigational and typically not covered
    Coverage implicationServices labeled investigational/experimental/unproven in this policy are subject to noncoverage and potential denial
    Examples citedSPG blocks, many migraine surgeries, and peripheral nerve stimulation for occipital neuralgia are listed as investigational/unproven in the policy
    inv-156: Temporary electrode trial definition
    Temporary electrode trial definitionA temporary electrode trial applies external leads and a generator for approximately one week to assess clinical response before permanent implantation
    Typical trial detailsUses temporary electrodes and external generator; response assessment guides decision for permanent implant
    Documentation expectationProviders should document trial duration, stimulation parameters, and clinical response (eg, pain reduction) in the record
    inv-157: Permanent PNS system definition
    Permanent PNS system definitionA system using multi‑contact electrodes tunneled subcutaneously and connected to an implanted generator (IPG) or microstimulator for chronic stimulation
    Typical componentsMulti‑contact leads (4–8 contacts), extension/tunneling to a subcutaneous generator pocket (eg, infraclavicular), and percutaneous or open implantation techniques
    Clinical pathwayPermanent PNS usually follows a successful temporary trial and appropriate psychological screening
    inv-158: Responder (ONSTIM definition)
    Responder (ONSTIM definition)Responder defined as achieving >50% reduction in headache days per month or a >3‑point reduction in pain severity; ONSTIM reported 39% responder rate with active stimulation
    Trial contextONSTIM used this definition as primary responder metric though the trial was not powered for efficacy
    ApplicationThis responder definition is used to interpret PNS trial outcomes in chronic headache studies
    inv-159: Theta/Beta power ratio (EEG) definition
    Theta/Beta power ratio (EEG) definitionA QEEG metric reflecting relative power in theta versus beta frequency bands; elevated frontal theta/beta ratio has been associated with ADHD in some studies
    Clinical cautionAAN guideline advises against using theta/beta ratio to replace standard clinical evaluation for ADHD due to high false‑positive risk
    Evidence statusQEEG applications remain formative and are not routinely incorporated into standard clinical practice for most indications
    inv-160: Seizure definition
    Seizure definitionA seizure is a transient focal or generalized sign or symptom due to abnormal excessive or synchronous neuronal activity in the brain
    ClassificationSeizures are broadly classified as focal, multifocal, or generalized based on onset and spread
    Clinical goalManagement aims to control seizures, minimize treatment side effects, and preserve quality of life
    inv-161: Partial (focal) onset seizure definition
    Partial (focal) onset seizure definitionSeizures originating within neuronal networks limited to one cerebral hemisphere, producing signs/symptoms corresponding to the affected brain region
    Clinical relevancePartial‑onset seizures are the primary target for responsive cortical neurostimulation and certain DBS epilepsy criteria
    Diagnostic requirementAccurate localization via EEG/imaging is necessary to establish focal seizure onset
    inv-162: Sphenopalatine ganglion (SPG) block definition
    Sphenopalatine ganglion (SPG) block definitionTopical or injected administration of local anesthetic to the SPG via intranasal access posterior and superior to the tail of the middle turbinate
    Target anatomySPG located near the posterior aspect of the middle nasal turbinate; access achieved via mucosal area posterior‑superior to the turbinate tail
    Delivery devicesDevices such as Tx360 and SphenoCath facilitate transnasal delivery of anesthetic to the SPG
    inv-163: Tx360 / SphenoCath device definitions
    Tx360 definitionTx360 is a nasal applicator device developed to facilitate transnasal delivery of medication to the sphenopalatine ganglion
    SphenoCath definitionSphenoCath is an ENT drug administration device (FDA Class I) used to deliver agents intranasally to the SPG; not marketed specifically as a migraine treatment
    Clinical noteBoth devices are described as methods to improve ease and consistency of SPG blockade delivery